# MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06549751/  
OnCo record `nct06549751` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MT-601 run by Marker Therapeutics, Inc., not yet recruiting.

## Summary

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer is a phase 1 interventional study registered as NCT06549751 by Marker Therapeutics, Inc., with 38 participants planned, started 2026-07-16. Conditions recorded: Pancreas Cancer, Pancreatic Cancer Metastatic and Pancreatic Cancer (Unresectable). Interventions recorded: MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells and MT-601 dose 1200 million cells.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06549751
- Phase: 1
- Setting: A Phase 1 Study With Expansion of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PANACEA)
- Sponsor: Marker Therapeutics, Inc.
- Enrolled: 38

## Sources

- ClinicalTrials.gov NCT06549751: https://clinicaltrials.gov/study/NCT06549751

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [MT-601](https://onco.cc/drugs/mt-601/)
- companies: [Marker Therapeutics](https://onco.cc/companies/marker-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06549751.json